Lung Cancer Clinical Trial
A Study of Pemetrexed Plus Carboplatin, or Pemetrexed Plus Cisplatin With Radiation Therapy Followed by Pemetrexed in Patients With Inoperable Non-Small-Cell Lung Cancer
Summary
The primary purpose of this study is to determine the 2-year survival rate of both of the chemotherapy regimens in patients with inoperable non-small-cell lung cancer.
Eligibility Criteria
Inclusion Criteria:
Inoperable non small cell lung cancer
No weight loss greater than 10% in 3 months prior to enrolling in trial
Adequate kidney function
Adequate liver function
Adequate lung function
Exclusion Criteria:
Previous surgery to remove lung tumor
Previous chemotherapy or radiation therapy or lung cancer
Inability to take vitamin supplementation
Heart attack within past 6 months
Active infection
Check Your Eligibility
Let’s see if you might be eligible for this study.
What is your age and gender ?
There are 11 Locations for this study
Los Angeles California, 90095, United States
Wichita Kansas, 67214, United States
St Louis Missouri, 63110, United States
Las Vegas Nevada, 89135, United States
Burlington North Carolina, 27216, United States
Memphis Tennessee, 38120, United States
Corpus Christi Texas, 78405, United States
Dallas Texas, 75390, United States
Temple Texas, 76508, United States
Delhi , 11008, India
Trivandrum , 695 0, India
How clear is this clinincal trial information?
Please confirm you are a US based health care provider:
Yes, I am a health care Provider No, I am not a health care providerSign Up Now.
Take Control of Your Disease Journey.
Sign up now for expert patient guides, personalized treatment options, and cutting-edge insights that can help you push for the best care plan.